Dashboard
Manage Tickers

DCTH DELCATH SYSTEMS, INC.

Nasdaq delcath.com


$ 11.31 $ -0.04 (-0.31 %)    

Tuesday, 21-Oct-2025 17:54:21 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 610.98 $ 0.00 (0 %)
DIA $ 469.20 $ 0.00 (0 %)
SPY $ 671.64 $ 0.00 (0 %)
TLT $ 91.99 $ 0.00 (0 %)
GLD $ 377.50 $ 0.00 (0 %)
$ 11.385
$ 11.40
$ 11.39 x 29
$ 11.75 x 25
-- - --
$ 8.87 - $ 18.23
1,153,436
na
398.26M
$ 1.15
$ 178.43
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-26-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-22-2023 03-31-2023 10-Q
11 03-27-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-31-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-25-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 07-17-2019 03-31-2019 10-Q
27 06-14-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-16-2018 12-31-2017 10-K
32 11-14-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-29-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-15-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 03-18-2016 12-31-2015 10-K
40 11-10-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

canaccord-genuity-maintains-buy-on-delcath-systems-maintains-21-price-target
Canaccord Genuity Maintains Buy on Delcath...
10/21/2025 16:29:32

Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $21 price target.

hc-wainwright--co-maintains-buy-on-delcath-systems-lowers-price-target-to-30
HC Wainwright & Co. Maintains Buy on Delca...
10/20/2025 15:49:16

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the pri...

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

reported-saturday-delcath-systems-phase-2-chopin-study-achieves-primary-endpoint-with-php-plus-immunotherapy-extending-median-pfs-to-128-months-versus-83-months
Reported Saturday, Delcath Systems' Phase ...
10/20/2025 07:53:35

reported-saturday-delcath-systems-posts-205m-q3-revenue-08m-net-income-and-87-gross-margin-sees-2025-revenue-outlook-of-83m85m-with-150-treatment-volume-growth-forecast
Reported Saturday, Delcath Systems Posts $...
10/20/2025 07:52:10

Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEP...

delcath-systems-announces-the-acceptance-of-an-oral-presentation-on-results-from-the-investigator-initiated-chopin-randomized-phase-2-trial-at-the-2025-european-society-for-medical-oncology-annual-congress
Delcath Systems Announces The Acceptance O...
09/22/2025 20:03:33

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

delcath-systems-doses-first-patient-in-phase-2-clinical-trial-of-hepzato-for-liver-dominant-metastatic-colorectal-cancer
Delcath Systems Doses First Patient In Pha...
08/19/2025 12:38:41

hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-31
HC Wainwright & Co. Maintains Buy on Delca...
08/07/2025 11:17:02

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

delcath-systems-sees-fy25-total-chemosat-and-hepzato-kit-revenue-93m-96m
Delcath Systems Sees FY25 Total CHEMOSAT A...
08/06/2025 12:03:02

delcath-systems-q2-eps-007-beats-002-estimate-sales-2416m-beat-2283m-estimate
Delcath Systems Q2 EPS $0.07 Beats $0.02 E...
08/06/2025 12:01:41

Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.02...

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

stephens--co-reiterates-overweight-on-delcath-systems-maintains-25-price-target
Stephens & Co. Reiterates Overweight on De...
06/23/2025 15:01:43

Stephens & Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:DCTH) with a Overweight and maintains $25 pri...

tesla-to-rally-around-47-here-are-10-top-analyst-forecasts-for-friday
Tesla To Rally Around 47%? Here Are 10 Top...
05/23/2025 15:14:21

hc-wainwright--co-maintains-buy-on-delcath-systems-raises-price-target-to-29
HC Wainwright & Co. Maintains Buy on Delca...
05/23/2025 10:38:01

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) with a Buy and raises the pri...

delcath-systems-sees-2025-chemosat-and-hepzato-kit-revenue-climbing-to-94m98m-in-2025-up-over-150-yoy-sees-8385-gross-margins
Delcath Systems Sees 2025 CHEMOSAT And HEP...
05/22/2025 11:08:24

2025 Full Year Total Revenue Guidance of $94 to $98 millionDelcath Announces Plan to Enter into National Medicaid Drug Rebate A...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/08/2025 17:06:16

delcath-systems-q1-eps-003-beats-001-estimate-sales-1980m-beat-1683m-estimate
Delcath Systems Q1 EPS $0.03 Beats $0.01 E...
05/08/2025 11:35:15

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

eagle-financial-services-nvidia-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
Eagle Financial Services, Nvidia And Other...
04/28/2025 12:37:49

delcath-systems-receives-fda-clearance-of-ind-application-for-phase-2-clinical-trial-of-hepzato-in-liver-dominant-metastatic-breast-cancer
Delcath Systems Receives FDA Clearance Of ...
04/28/2025 12:35:40

Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic live...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION